Richard P Schlegel

Author:

Richard Schlegel

ISBN #:

0226738418

Author:

Richard Schlegel

ISBN #:

0486222241

US Patent:

7989491, Aug 2, 2011

Filed:

Feb 12, 2004

Appl. No.:

10/545356

Inventors:

Richard Schlegel - Rockville MD, US
Astrid Baege - McLean VA, US

Assignee:

Georgetown University - Washington DC

International Classification:

A61K 31/357

US Classification:

514450, 514452

Abstract:

In certain aspects, the invention relates to methods of treating proliferative cervical disorders (such as cervical cancer and cervical dysplasia) and treating virus infections by administering artemisinin-related compounds. In certain aspects, the invention relates to methods of treating a tumor induced by an oncogenic virus, methods of killing or inhibiting a squamous cell carcinoma, and methods of inhibiting the replication of a virus, by administering artemisinin-related compounds.

US Patent:

8394849, Mar 12, 2013

Filed:

Jul 11, 2011

Appl. No.:

13/179978

Inventors:

Richard Schlegel - Rockville MD, US
Astrid Baege - McLean VA, US

Assignee:

Georgetown University - Washington DC

International Classification:

A61K 31/357

US Classification:

514450

Abstract:

In certain aspects, the invention relates to methods of treating proliferative oropharyngeal cancer, laryngeal cancer and esophageal cancer by administering artemisinin-related compounds.

US Patent:

20070065810, Mar 22, 2007

Filed:

Jul 16, 2004

Appl. No.:

10/565021

Inventors:

Richard Schlegel - Rockville MD, US

International Classification:

C12Q 1/70
C12Q 1/68

US Classification:

435005000, 435006000

Abstract:

In certain aspects, the invention relates to methods of diagnosing cervical cancer by using a combination of certain biomarkers such as hTERT, IGFBP-3, transferrin receptor, beta-catenin, Myc-HPV E6 interaction, HPV E7, and telomere length. In other aspects, the invention relates to methods of detecting immortalization of cervical cells by using a combination of certain biomarkers. In yet other aspects, the invention relates to methods of classifying the grade of a cervical lesion for diagnostic and prognostic purposes in a female. In further aspects, the invention relates to methods of treating cervical cancer by administering a therapeutic agent that targets one or more of these biomarkers.

US Patent:

20080113340, May 15, 2008

Filed:

Jan 11, 2008

Appl. No.:

12/008532

Inventors:

Richard Schlegel - Rockville MD, US

Assignee:

Georgetown University - Washington DC

International Classification:

C12Q 1/70
C12Q 1/68
G01N 33/574
A61K 48/00
A61K 38/17
A61K 31/47

US Classification:

435005000, 435007230, 435006000, 514044000, 514012000, 514310000

Abstract:

In certain aspects, the invention relates to methods of diagnosing cervical cancer by using a combination of certain biomarkers such as hTERT, IGFBP-3, transferrin receptor, beta-catenin, Myc-HPV E6 interaction, HPV E7, and telomere length. In other aspects, the invention relates to methods of detecting immortalization of cervical cells by using a combination of certain biomarkers. In yet other aspects, the invention relates to methods of classifying the grade of a cervical lesion for diagnostic and prognostic purposes in a female. In further aspects, the invention relates to methods of treating cervical cancer by administering a therapeutic agent that targets one or more of these biomarkers.

US Patent:

20100151466, Jun 17, 2010

Filed:

Oct 7, 2009

Appl. No.:

12/575431

Inventors:

Richard Schlegel - Rockville MD, US

Assignee:

Georgetown University - Washington DC

International Classification:

C12Q 1/68
C12Q 1/02
C12Q 1/48

US Classification:

435 6, 435 29, 435 15

Abstract:

In certain aspects, the invention relates to methods of diagnosing cervical cancer by using a combination of certain biomarkers such as hTERT, IGFBP-3, transferrin receptor, beta-catenin, Myc-HPV E6 interaction, HPV E7, and telomere length. In other aspects, the invention relates to methods of detecting immortalization of cervical cells by using a combination of certain biomarkers. In yet other aspects, the invention relates to methods of classifying the grade of a cervical lesion for diagnostic and prognostic purposes in a female. In further aspects, the invention relates to methods of treating cervical cancer by administering a therapeutic agent that targets one or more of these biomarkers.

US Patent:

20130309681, Nov 21, 2013

Filed:

Nov 11, 2011

Appl. No.:

13/885078

Inventors:

Richard Schlegel - Rockville MD, US
Xuefeng Liu - Gaithersburg MD, US

Assignee:

Georgetown University - Washington DC

International Classification:

C12N 5/071

US Classification:

435 612, 435184, 435375

Abstract:

The present invention is directed towards methods of culturing non-keratinocyte epithelial cells, with the methods comprising culturing non-keratinocyte epithelial cells in the presence of feeder cells and a calcium-containing medium while inhibiting the activity of Rho kinase (ROCK) in the feeder cell, the non-keratinocyte epithelial cells or both during culturing.

US Patent:

55762069, Nov 19, 1996

Filed:

May 20, 1994

Appl. No.:

8/246704

Inventors:

Richard Schlegel - Rockville MD

Assignee:

Georgetown University

International Classification:

C12N 522
C12N 1585

US Classification:

4352402

Abstract:

A process of immortalizing cells with isolated HPV-16, 18, 31, 33 or 35 E6 and E7 genes or the E7 gene alone to produce non-tumorigenic immortalized cell lines which retain the differentiated phenotypic characteristics of the parent cells.

US Patent:

20140322809, Oct 30, 2014

Filed:

Nov 20, 2013

Appl. No.:

14/085309

Inventors:

- Bethesda MD, US
- Washington DC, US
Richard Schlegel - Rockville MD, US
Xuefeng Liu - Gaithersburg MD, US

Assignee:

The United States of America as Represented by the Secretary, Department of Health and Human Service - Bethesda MD
Georgetown University - Washington DC

International Classification:

C12N 5/071

US Classification:

435373

Abstract:

Disclosed herein is the finding that treatment with a ROCK inhibitor increases proliferation and induces immortalization of primary keratinocytes. Accordingly, provided is a method of immortalizing primary keratinocytes by exposure to a ROCK inhibitor. Also provided are immortalized primary keratinocytes produced by the described method, as well as organotypic tissue equivalents and cell cultures comprising the immortalized primary keratinocytes. Furthermore, ROCK inhibitor-treated cells show a greatly increased ability to support viral DNA replication of both “low risk” and “high risk” HPV genomes, indicating that ROCK inhibitors will be useful for studying the life cycles of a wide range of HPVs.

Address:

3509 Thornapple St, Chevy Chase, MD 20815

Phone:

3016560427

VIN:

WDBUF22X07B226185

Make:

MERCEDES-BENZ

Model:

E-CLASS

Year:

2007